LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LLY is a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. My direct view is BUY. The stock has strong upward momentum, supportive news catalysts, and a constructive analyst backdrop. Although options positioning is mixed and Congress trading is slightly bearish, the long-term growth story and recent demand/coverage improvements outweigh those concerns. Given the investor is impatient and does not want to wait for a perfect entry, this is a reasonable buy now rather than a stock to avoid.
Technically, LLY is in a clear bullish trend. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports trend continuation. MACD histogram is positive and expanding at 4.415, showing strengthening momentum. RSI_6 is 70.254, which is elevated but still described as neutral here, so momentum is strong without a clear reversal signal from the provided data. Price at 1212.25 is near R1 at 1219.588 and below R2 at 1257.06, suggesting the stock is pressing into resistance but remains in an uptrend. The short-term pattern data also points positive, with a 60% chance of a 3.54% move next day, 2.2% next week, and 8.41% next month.
["Strong recent price surge driven by favorable drug approvals and improved market position", "European Medicines Agency recommendation for Jaypirca", "Medicare coverage expansion for obesity drugs, improving access for seniors", "CMS GLP-1 Bridge program and $50 copay access, which could lift demand and revenue", "Analysts continue to raise price targets, with several bullish calls in May and June", "Long-term structural growth in GLP-1 and obesity treatment markets"]
["Options open interest suggests some hedging/caution, with put open interest above call open interest", "Congress trading shows more selling than buying over the last 90 days", "RSI is elevated, so the stock is already extended after the recent rally", "A recent safety-related news item around Foundayo created temporary concern, even though analysts viewed it as overdone"]
No full quarterly financial snapshot was provided because the financial data returned an error. Based on the news and analyst notes, the latest quarter appears to have been strong, with Q1 results supporting upward estimate revisions, stronger tirzepatide momentum, better earnings leverage, and raised 2026 guidance. The latest referenced quarter is Q1 2026, and the comments indicate growth remained robust in Lilly's GLP-1 franchise and obesity-related business.
Wall Street remains constructive overall. Recent analyst actions show multiple price target increases, including Leerink to $1,232 with Outperform, BofA to $1,251 with Buy, Guggenheim to $1,235 with Buy, Barclays to $1,400 with Overweight, Morgan Stanley to $1,344 with Overweight, and Cantor to $1,230 with Overweight. There is one Hold rating from Berenberg, but the overall trend is clearly upward in price targets and mostly bullish in ratings. Pros: strong franchise momentum, market expansion, and repeated target raises. Cons: some analysts remain more cautious on valuation, and the stock has already rallied sharply.
